Skip Navigation

JNCI Journal of the National Cancer Institute 2005 97(14):1030; doi:10.1093/jnci/dji227
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Washam, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Washam, C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 Oxford University Press

NEWS

Two HPV Vaccines Yielding Similar Success

Cynthia Washam

The first 10% of the full text of this article appears below.

New Jersey-based Merck & Co., and GlaxoSmithKline (GSK), based in England, are in the final phase of clinical trials of their vaccines against human papillomavirus (HPV) types . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 The OncologistHome page
I. de Melo-Martin
The promise of the human papillomavirus vaccine does not confer immunity against ethical reflection.
Oncologist, April 1, 2006; 11(4): 393 - 396.
[Abstract] [Full Text] [PDF]